Authors: Judith Aron-Wisnewsky, Moritz V Warmbrunn, Max Nieuwdorp, Karine Clément.
Gastroenterology 160, 2 (2021). doi: 10.1053/j.gastro.2020.10.057
PubMed Id: 33253685


Abstract: Changes in the intestinal microbiome have been associated with obesity and type 2 diabetes, in epidemiological studies and studies of the effects of fecal transfer in germ-free mice. We review the mechanisms by which alterations in the intestinal microbiome contribute to development of metabolic diseases, and recent advances, such as the effects of the microbiome on lipid metabolism. Strategies have been developed to modify the intestinal microbiome and reverse metabolic alterations, which might be used as therapies. We discuss approaches that have shown effects in mouse models of obesity and metabolic disorders, and how these might be translated to humans to improve metabolic health.